Acta Scientific Ophthalmology (ISSN: 2582-3191)

Volume 8 Issue 8 August 2025

Research Article

Precision Therapy in Fabry Disease: Evaluating Migalastat's Impact on Cardiac, Renal, and Neurological Outcomes

Tejas Jain*

Coventry University, England

***Corresponding Author:** Tejas Jain, Coventry University, England.

Received: June 26, 2025

Published: July 30, 2025

Abstract

Another name for Fabry disease (FD) is Anderson-Fabry disease. Changes in the GLA gene cause globotriaosylceramide (Gb3) to accumulate and α-galactosidase A (α-Gal A) to be deficient in FD, an orphan X-linked lysosomal storage disorder (LSD). Consequently, multiple organs fail, particularly the heart, kidneys and neurological system. Present therapies include pharmaceutical chaperone therapy (PCT) and enzyme replacement therapy (ERT). An example of PCT is migalastat (Galafold), an oral chaperone that stabilizes certain α-Gal A mutations. The goal of emerging therapeutics like gene therapy and drug delivery based on nanotechnology is to enhance treatment results. The pathophysiology, clinical presentations, and therapeutic developments of FD are examined in this review.

Keywords: Lysosomal Storage; Galafold; Alpha-Gal A; Fabry Disease; Enzyme Replacement Therapy; Nanotechnology

Introduction

The X-linked genetic condition known as Fabry disease (FD) is brought on by mutating the GLA gene. This disorder causes globotriaosylceramide (Gb3) to build up inside cells due to a lack of the enzyme α-galactosidase A (α-Gal A). The kidneys, heart, and neurological system are among the organs that are impacted over time by this accumulation [1,2]. Although the initial symptoms of this degenerative disease may include neuropathic pain, hypohidrosis, corneal opacities, and angiokeratomas. This primarily target the neurological, cardiac, and renal systems. Cardiac problems, including fibrosis, arrhythmias, and left ventricular hypertrophy (LVH), are leading causes of morbidity and death [3]. Migalastat, known as Galafold, is one way to treat certain mutations in α-Gal A. It increases the enzyme's activity and stabilises it [2]. According to calculations, the estimated prevalence of FD is 1 in 3,000. The incidence among female carriers ranges from 1:6,000 to 1:40,000 [4]. Migalastat is a good choice for some patients because it's taken as a pill and doesn't cause an immune response. But keep in mind, it only works for specific GLA mutations. New treatments like gene therapy, substrate reduction therapy, and drug delivery using tiny tech aim to work better for patients. Plus, machine learning and AI are making it easier to keep track of diseases and catch them early [3].

Clinical pitcher of fabry disease

Fabry disease is a lysosomal storage disease that affects many systems in the body. Because of this, it can lead to different symptoms affecting the nervous system, heart, kidneys, and digestive system. How bad the disease depends on the specific GLA gene mutation and how much α-Gal A activity is left [4,5].

Early signs

- **Nerve pain:** This often feels like burning or tingling in your hands and feet. Stress, exercise, or changes in temperature can trigger it [2].
- **Being really sensitive to heat:** This can happen if you don't sweat enough, or at all.

- **Angiokeratomas:** These are dark red or purple spots on your skin, and they usually show up on your torso.
- **Corneal verticillata:** These are swirls that appear in your corneas, but they don't mess with your vision.
- **Upset stomach:** This can show up as nausea, bloating, diarrhea, and pain in your belly [2,3].

Serious health issues

- Kidney failure, or ESRD, happens when your kidneys get worse over time, causing protein in your pee and kidney problems. Often, people with ESRD need dialysis or a kidney transplant.
- Heart problems can show up as an enlarged left ventricle (LVH), which can cause heart failure.

Other heart issues include:

- Irregular heartbeats, like ventricular tachycardia and atrial fibrillation.
- Problems with the heart's electrical system and scarring.
- Brain problems, like strokes and TIAs, are more common because of a buildup of Gb3 in the brain's arteries. This can also cause damage to the brain's white matter.
- Vision and Hearing Problems: Ringing in the ears and hearing loss. Vortex keratopathy, which causes golden-brown spots on the cornea of the eye.
- Different Symptoms: Men with classic Fabry disease usually have severe symptoms that start early because they don't have enough of a certain enzyme.
- Women who carry the Fabry disease gene can have different symptoms. Some might have serious damage to their organs, while others might not have any symptoms at all [2,3].

Current therapies for fabry disease

Fabry disease (FD) can be treated with pharmacological chaperone therapy (PCT), enzyme replacement therapy (ERT), substrate reduction therapy (SRT), gene therapy, and more recent mRNA-based methods. The patient's genetic mutation, the severity of the condition, and the organs impacted all influence the optimal course of treatment. In order to properly manage symptoms and reduce the progression of the condition, a customised approach is frequently required [3].

Enzyme replacement therapy, or ERT

Basically, they inject a lab-made version of the missing enzyme (α-Gal A) right into your veins. Here are some ERTs:

- Agalsidase alfa (Replagal) is given every couple of weeks. It's approved in Europe, but not in the US.
- Agalsidase beta (Fabrazyme) is approved by the FDA and requires a bigger dose than agalsidase alfa.
- Pegunigalsidase alfa (Elfabrio) is a longer-lasting option. It might be better at getting into the kidneys and less likely to cause an immune response [6].

Substrate reduction therapy (SRT)

- SRT stops Gb3 from building up by blocking its creation. It's a different approach than using enzymes. Venglustat and Lucerastat are currently under clinical studies.

Pharmacological chaperone therapy (PCT) migalastat

- Migalastat (Galafold), a pill you swallow, works like a special helper. It strengthens an enzyme and gets lysosomes working better by attaching to certain messed-up parts of it [6,7].

Effectiveness

- Only works in those with GLA mutations that are susceptible (around 35–50% of FD cases). Similar to ERT, it has cardiac and renal advantages without inducing immunological reactions. Before starting, genetic testing is necessary [6].

Limitations

Only works on those who have GLA mutations that are susceptible.

Less effective in patients with severe mutations causing complete enzyme loss.

Migalastat characteristics and pharmacological properties

Migalastat, prescribed under the brand name Galafold, is a drug that helps treat Fabry disease. It works for people with certain changes in the GLA gene. This medicine helps some faulty versions of an enzyme called α-galactosidase A. By doing this, it boosts the

Brain	Eyes	Ears	Heart	Blood vessels	Skin
Ischemic Strokes	Vortex Keratopathy	Tinnitus	Arrhythmia	Increase thickness	Angiokeratoma
Lesions in white matter		Hearing loss	Hypertropic cardiomayopathy		
Congnitive impairment			Conduction defect		
			Valvular disease		

Table 1: Clinical Manifestation of Fabry Disease. Adapted from (Raj., *et al*. 2024).

enzyme's activity in the lysosomes. This helps reduce the build-up of a fat called globotriaosylceramide, which happens when the enzyme isn't working well [8].

Pharmacological properties

Mechanism of action

Migalastat helps some faulty α-Gal A enzymes. It makes them fold the right way and guides them to the lysosome. It does this by attaching to their active site. Once migalastat is let go inside the lysosome, the enzyme can break down Gb3 and its product, lyso-Gb3. This approach means we don't need to keep giving enzyme infusions all the time. It really helps the enzyme work better [3].

Pharmacokinetics

Parameters	Details
Absorption	Orally absorbed, reaches peak plasma concentration in 2-3 hours.
Distribution	Good protein binding; distributes into lysosomes where alpha-Gal A is active.
Metabolism	Minimally metabolized by hepatic enzymes.
Excretion	Eliminated via urine. Half-life: 4-6 hours; requires dosing every other day.

Table 2: Pharmacokinetic Properties of Drug (Drug.com, 2025).

Clinical efficacy and safety

Clinical studies show that migalastat can really cut down on Gb3 buildup in people with certain mutations, and it seems to help their kidneys and heart work better while keeping neurological issues stable. It's generally safe, with most people only experiencing mild stomach problems. Unlike ERT, migalastat is a less invasive option that targets specific mutations, making it a precise way to treat Fabry disease. Just keep in mind, it only works for those with particular GLA mutations, so genetic testing is a must before starting treatment [3].

Structure

- **Core Scaffold:** The molecule is a pyranose, which is a six-membered ring that contains oxygen. It has a structure similar to that of a sugar, which is a monosaccharide.
- **Functional group:** Contributes to its interaction with α-galactosidase A (α-Gal A) is the amino group (-NH).
- **Hydroxyl groups (-OH):** Make substances more soluble and enable them to form hydrogen bonds with enzymes [9].



Figure 1: Migalastat 2D structure (PubChem, 2025).

Therapeutic efficacy of migalastat in farbry disease depending on the organs involved

Migalastat (Galafold) is an oral drug for Fabry disease (FD) that works best in folks with certain GLA mutations. It stabilizes a mutated enzyme, α-Gal A, and helps it work better in cells. How well it works can depend on which organs are affected by the disease [7].

Renal efficacy

Chronic kidney disease (CKD), proteinuria, and glomerular degeneration are the hallmarks of Fabry disease, which causes progressive renal impairment. Migalastat has demonstrated effectiveness in maintaining renal function. In patients with amenable mutations, clinical trials showed a sustained estimated glomerular filtration rate (eGFR) for a period of 24 to 36 months. Renal podocytes showed a marked decrease in Gb3 deposits, indicating that migalastat can remove substrate buildup. However, migalastat proved less effective than enzyme replacement therapy (ERT) in advanced chronic kidney disease (CKD) (GFR <45 mL/min/1.73 m^2) [3,6,7].

Cardiac efficacy

With Fabry disease (FD), the heart can have problems like irregular heartbeats, tissue thickening, and an enlarged left ventricle. Studies show Migalastat can really help:

- It lowers the size of the left ventricle, and this gets better over time.
- It cuts down on a certain buildup in heart cells and makes the heart work better, which means the disease is not getting worse.
- It helps with heartbeat problems, but some folks who have a lot of tissue thickening might need more help [6,7].

Neurological efficacy

- Fabry disease can lead to problems like white matter issues, nerve damage in your arms and legs, and strokes. Migalastat might not fix brain damage that's already there, but it could prevent things from getting worse.
- We are still learning how it affects blood flow in the brain, but some research suggests it can keep white matter lesions from growing. Enzyme replacement therapy (ERT) is often used for serious nerve problems, but migalastat does not seem to help much with nerve pain [7].

Migalastat dosage

Recommended dosage

- **Strength:** 123 mg capsules.
- **Frequency:** One capsule every other day at the same time.
- **Administration:** Swallow the capsule whole; do not cut, crush, or chew.

Administration instructions

Take Migalastat on empty stomach (fasting required). Avoid food for at least 2 hours before and after administration [10].

Side effects and adverse effect

Side Effect	Description
Headaches	Often reported by individuals taking the medication.
Nausea	A frequent digestive issue, causing stomach discomfort.
Fever (Pyrexia)	Temporary rise in body temperature.
Nasopharyngitis	Cold-like symptoms, including congestion and sore throat.
Diarrhea	Stomach troubles, including loose stools.
Back Pain	Mild to moderate discomfort in the back.

Table 3: Common Side Effects (Drugs.com, 2024) (Migalastat, 2024).

Serious adverse effects

- **Urinary Tract Infections (UTIs):** Clinical studies have reported UTIs as a potential concern. Patients should be aware of symptoms such as pain during urination, frequent urges to urinate, and cloudy or strong-smelling urine.
- **Allergic Reactions:** Though rare, severe allergic reactions can occur. Skin rashes, itching, swelling, light-headedness, and trouble breathing are warning indications. If any of these symptoms develop, immediate medical attention is necessary [8].

Cost effectiveness of migalastat

Adults with an amenable mutation and a verified diagnosis of alpha-galactosidase A deficiency are treated for Fabry disease over the long term with migalastat (Galafold). For consistency, patients take 123 mg at the same time every other day. The approximate cost of each capsule is $1,700, which adds up to about $310,250 per patient annually. This price is similar to what intravenous enzyme replacement therapy (ERT) prices that are available to the general population. In contrast to ERT, migalastat is only prescribed for patients who have a mutation that qualifies them for the treatment [10-15].

Conclusion

A significant development in the treatment of Fabry disease is migalastat (Galafold), especially for those who have unique GLA mutations that react to it. Compared to enzyme replacement therapy (ERT), this oral drug offers a more convenient choice, which may help patients stick to their treatment plan. It helps reduce the buildup of globotriaosylceramide (GL-3) in vital organs such as the heart, kidneys, and nervous system by stabilising α-galactosidase A (α-Gal A).

Despite its many advantages, migalastat's efficacy varies based on the organ impacted and the patient's genetic composition. Even though trials show promising results, more thorough investigation is required to completely comprehend how well it slows the advancement of the disease over time. Its cost-effectiveness as an alternative to ERT is likewise a topic of continuous discussion, necessitating additional economic research.

To put it briefly, migalastat offers a promising, less invasive method of treating Fabry disease. To maximise its utilisation and enhance long-term patient care, however, more research and evaluations will be necessary.

Bibliography

1. Miller JJ., *et al*. "Progress in the understanding and treatment of Fabry disease". *Biochimica et Biophysica Acta (BBA) - General Subjects* 1864.1 (2020): 129437.

2. Raj A., *et al*. "Fabry disease management: Current status, therapeutic challenges, and future horizons in drug delivery and artificial intelligence assisted diagnosis". *Journal of Drug Delivery Science and Technology* 100 (2024): 106032-106032.

3. Weissman D., *et al*. "Fabry Disease: Cardiac Implications and Molecular Mechanisms. *Current Heart Failure Reports* 21.2 (2024): 81-100.

4. Palaiodimou L., *et al*. "Fabry Disease: current and novel therapeutic strategies. A narrative review". *Current Neuropharmacology* (2022): 20.

5. Päivi Pietilä-Effati., *et al*. "Long-term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study". *American Journal of Medical Genetics. Part A* 191.7 (2023): 1858-1869.

6. Yoo H. "Fabry disease: current treatment and future perspective". *Journal of Genetic Medicine* 20.1 (2023): 6-14.

7. Nowicki M., *et al*. "A review and recommendations for oral chaperone therapy in adult patients with Fabry disease". *Orphanet Journal of Rare Diseases* 19.1 (2024).

8. Migalastat. Go.drugbank.com (2024).

9. PubChem. Migalastat. Nih.gov; PubChem (2025).

10. Canadian Agency for Drugs and Technologies in Health. Executive Summary. Nih.gov; Canadian Agency for Drugs and Technologies in Health (2018).

11. Migalastat Side Effects: Common, Severe, Long Term. Drugs.com (2024).

12. Germain D P., *et al*. "Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat". *New England Journal of Medicine* 375.6 (2016): 545-555.

13. Kugadas A., *et al*. "Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients". *PLOS ONE* 19.5 (2024): e0304415.

14. Malte Lenders., *et al*. "Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease". *Orphanet Journal of Rare Diseases* 20.1 (2025).

15. New drug: Migalastat for Fabry disease. Australian Prescriber 42.1 (2018): 29.